Combined use of subclinical hydroxyurea and CHK1 inhibitor effectively controls melanoma and lung cancer progression, with reduced normal tissue toxicity compared to gemcitabine. Issue 7 (14th June 2019)

• Record Type: Journal Article
• Authors: Oo, Zay Yar; Proctor, Martina; Stevenson, Alexander J.; Nazareth, Deborah; Fernando, Madushan; Daignault, Sheena M.; Lanagan, Catherine; Walpole, Sebastian; Bonazzi, Vanessa; Škalamera, Dubravka; Snell, Cameron; Haass, Nikolas K.; Larsen, Jill E.; Gabrielli, Brian
• Is Part Of: Molecular oncology. Volume 13:Issue 7(2019)
• Page Start: 1503
• Page End: 1518
• Publication Date: 2019-06-14
• Subjects: CHK1 inhibitor -- hydroxyurea -- macrophage infiltration -- replication stress; Cancer -- Molecular aspects -- Periodicals; 616.994005
• DOI: 10.1002/1878-0261.12497
• Languages: English
• ISSNs: 1574-7891

Abstract

Abstract : Drugs such as gemcitabine that increase replication stress are effective chemotherapeutics in a range of cancer settings. These drugs effectively block replication and promote DNA damage, triggering a cell cycle checkpoint response through the ATR–CHK1 pathway. Inhibiting this signalling pathway sensitises cells to killing by replication stress‐inducing drugs. Here, we investigated the effect of low‐level replication stress induced by low concentrations (> 0.2 mm ) of the reversible ribonucleotide reductase inhibitor hydroxyurea (HU), which slows S‐phase progression but has little effect on cell viability or proliferation. We demonstrate that HU effectively synergises with CHK1, but not ATR inhibition, in > 70% of melanoma and non‐small‐cell lung cancer cells assessed, resulting in apoptosis and complete loss of proliferative potential in vitro and in vivo . Normal fibroblasts and haemopoietic cells retain viability and proliferative potential following exposure to CHK1 inhibitor plus low doses of HU, but normal cells exposed to CHK1 inhibitor combined with submicromolar concentrations of gemcitabine exhibited complete loss of proliferative potential. The effects of gemcitabine on normal tissue correlate with irreversible ATR–CHK1 pathway activation, whereas low doses of HU reversibly activate CHK1 independently of ATR. The combined use of CHK1 inhibitor and subclinical HU also triggered an inflammatory response involving the recruitment of macrophages in vivo . These data indicate that combining CHK1 inhibitor with subclinical HU is superior to combination with gemcitabine, as it provides equal anticancer efficacy but with reduced normal tissue toxicity. These data suggest a significant proportion of melanoma and lung cancer patients could benefit from treatment with this drug combination. Abstract : Gemcitabine and 2 mm hydroxyurea (HU) produce high‐level replication stress triggering ATR–CHK1‐dependent S‐phase arrest. 0.2 mm HU triggers CHK1 activation (possibly without ATR involvement) and continued S‐phase progression by dormant origin firing. CHK1 inhibitors produce equivalent DNA damage and death with both treatments, with the combination with 0.2 mm HU producing less normal tissue toxicity.